The interactions of HSA with DA have received great attention nowadays due to its significant effect in the biomedical field and overall health. The main aim of this work is to examine the interaction between DA and HSA at physiological conditions. Upon addition of DA to HSA, the fluorescence emission was quenched with quenching constant K q = 1.32 × 10 9 L•mol −1
Introduction
Dopamine (DA), chemical structure provided in the top part of Figure 1 [1] , is a catecholamine neurotransmitter synthesized within the brain in the dopaminergic neurons and is involved in regulating multiple functions including movement and memory. DA transmits signals between neurons throughout human brain and body. The elevated or reduced dopamine level may cause memory loss related diseases, attention deficit, hyperactivity disorder, daydreaming and not being able to stay on task. Any changes in the levels of this vital neurotransmitter chemical have been proven to be related to several dopaminergic neurological diseases depending on the affected region in the brain [2] [3] [4] [5] . For example, neurocognitive disorders related to memory, attention, and problem-solving functions result from decline of DA in frontal lobes of the brain which controls the flow of information from other areas of the brain [6] [7] [8] .
Therefore, DA is considered a major target for drug designing applied in the treatment of neurological diseases.
Inadequate DA levels due to the loss of DA-producing cells have been related Parkinson's disease which is associated with a loss in the ability of well controlled movements [9] [10] [11] . Despite the ongoing research to understand these devastating disorders, the sophisticated causes of dopaminergic cells' loss in Parkinson's disease are only partially understood.
pounds [12] [13] . Recent investigation has demonstrated the capacity of subdomain IB in binding drugs making it a potential for various drugs delivery [15] .
These binding sites empower the HSA with an exceptional ability in binding various ligands, which adds to its biological importance in delivering number of drugs in the blood system to their targeting organs/tissues within the human body [16] [17] . Generally, HSA binds reversibly with wide range of drugs however some drugs with high affinity for HSA limit the drug distribution-of free form and the bound form-as well as the elimination of the drugs. In addition, the HAS-drug interactions play an important role in understanding the efficiency of the drug as determined by the free fraction of the drug [18] [19].
Alzheimer's Disease (AD)
AD, affecting millions of individuals worldwide, is an irreversible neurodegenerative disorder characterized by progressive cognitive decline and dementia [20] . The decline in cognitive function affects recent memory first then slowly spreads to other regions of the brain. As of now, the exact cause of AD is not known and currently there is no cure for this devastating disease. Therefore, any available treatment is meant to slow the progression of AD and relieves its symptoms. It has been suggested and well documented that AD originates in the brain [21] but a recent investigation have indicated that AD could have been triggered by breakdowns elsewhere in the body. This finding makes is promising in preventing AD from reaching the brain if proper drug targets the toxin protein and removes it while in the blood without the need to act directly on the brain, which is a very challenging task to accomplish and hard-to-reach target safely [22] [23] . In addition, electrical signaling responsible for learning and memory is usually diminished in people with AD [24] . ciency which is believed to be responsible neurodegenerative "motor disease". The main therapy to treat PD is by dopamine replacement merely relieves the associated symptoms but the disease continues its progression. Therefore, there is a need for understanding the process of the neurological degeneration to develop effective drugs to stop the degeneration [10] [11] .
In addition to PD, alterations in the dopamine levels have been consistently observed and reported in AD patients, including lower levels of dopamine (DA) mg/ml equivalent to molarity of 0.6 mM which is comparable to its concentration in the blood [15] . 
Thin Film Preparation
Silicon windows (NICODOM Ltd.) were used as spectroscopic cell window. 60 µl of each sample of HSA-DA was spread on silicon window using spincoater to obtain equal thickness of each sample, then incubator was used to evaporate the solvent to obtain transparent thin film on the silicon window. All solutions were prepared at the same time at room temperature and were stored under the same conditions.
Instrumentation

FT-IR Spectroscopic Measurements
The FT-IR measurements were obtained used Bruker IFS 66/S spectrophotometer equipped with a liquid nitrogen-cooled MCT detector and KBr beam splitter. Silicon windows (NICODOM Ltd) were used as spectroscopic cell windows. Complexes' solutions (0.15, 0.3, 0.6, 0.7, 0.9) mM were prepared at room temperature. 60 µL of each sample of HSA-DA was spread on silicon window using spin coater to obtain equal thickness of each sample, and then was incubated for two hours to evaporate the solvent in order to obtain transparent thin film on the silicon window. The spectrophotometer was continuously purged with dry air during the measurements. The absorption spectra were obtained in the range of (400 -4000) cm −1 . A spectrum was taken as an average of 60 scans to enhance the signal to noise ratio, and the spectral resolution was at 4 cm −1 . The aperture used in this study was 8 mm, since it gave the best signal to noise ratio. Baseline I. M. Khalid et al. Open Journal of Biophysics correction, normalization and peak areas calculations were performed for all the spectra by OPUS software. The peak positions were determined using the second derivative of the spectra. The infrared spectra of HSA and the HSA-DA complexes were obtained in the region of (1200 -1700) cm −1 . The FTIR spectrum of free HSA was acquired by subtracting the absorption spectrum of the buffer solution from the spectrum of the protein solution. For the net interaction effect, the difference spectra {(HSA-DA) -(HSA)} were generated using the featureless region of the spectra at (1800 -2200) cm −1 .
UV-VIS Absorption Spectra
The data was collected using 5 µL samples using NanoDrop ND-1000 Spectrophotometer for the free HSA (40 mg/ml or 0.6 mM) and for the HSA-DA complexes solutions with the following concentrations (0.15, 0.3, 0.4, 0.5, 0.6, 1.0, 1.2, and 2.4) mM. UV measurements were repeated for all the samples and no significant differences were observed. The UV-absorption spectra of HSA-DA complex are obtained at the wavelength of 280 nm.
Fluorescence
The fluorescence measurements were obtained using NanoDrop ND-3300 Flu- 
Results
UV-Absorption Spectroscopy
The UV absorbance spectra of different concentration of dopamine with a fixed concentration of HSA which were scanned over a range of 220 -350 nm are presented in Figure 2 . Each spectrum indicates two absorption maximum wavelengths at about 230 and 280 nm. The figure shows direct relationship between the increase in peak intensity of the HSA-DA complex and the concentration of the DA. This increase in intensity is due to interaction between HSA and DA as monitored in buffered solution by scanning the wavelengths. As indicated in the figure, there is a clear absorption signal for free DA.
The reciprocal plot of 1/(A − A o ) versus (1/l) is linear as indicated in Figure 3 . When a fixed concentration of HSA was allowed to complex with various amounts of DA, there is a linear increase in the UV absorbance of HSA. A binding constant for the HSA-DA complex was calculated using UV spectra according to published methods [16] with the assumption that there is one-to-one :
The corresponding formation/binding constant:
on the following equation.
where A o corresponds to the initial absorption of HSA at 280 nm in the absence of DA, A ∞ is the final absorption of the HSA, and A is the recorded absorption at concentration. This result supports the speculation that the interaction between HSA and DA is weak interaction.
Fluorescence Emission Spectroscopy
The emission spectra in the range of 400 to 750 nm were obtained for HSA-DA spectra are shown in very little changes is observed on the absorption spectra of the HSA shape as the DA concentration is added which is an indication of minor conformational changes due to collisional quenching [40] .
Further, to elucidate the nature of the quenching mechanism as static or dynamic in the HSA-DA system, Stern-Volmer equation [35] is used to plot F o /F versus l and the result is shown in Figure 5 . The Stern-Volmer plot is non-linear, indicating that both types of static and dynamic quenching occur. HSA is quenched both by collisions and by complex formation with DA. Hence,
where F and F 0 are the fluorescence intensities with and without quencher, K D is the dynamic quenching constant of the biomolecule and K sv is the Stern-Volmer quenching constant due to static quenching. This modified second order form of the Stern-Volmer equation with respect to DA concentration, accounts for the both static and dynamic quenching occur for the same fluorophore. When quenching is due to static quenching, the second parenthesis in Equation (4) is ignored and when the quenching is dynamic the first parenthesis is ignored. However, when both static and dynamic quenching are present, one must account for each type. Fluorescence quenching can be induced by different mechanisms, which are usually classified into dynamic and static quenching. Dynamic quenching arises from collisional encounters between the fluorophore and quencher, and static quenching resulting from the formation of a ground state complex between the fluorophore and the quencher [40] . Open Journal of Biophysics 
Accessibility of Tryptophan in HSA to Quenching by DA Using Fluorescence
When dynamic collisional quenching dominates as quenching type of fluores- 
FT-IR Spectroscopy
FT-IR is used widely to analyze IR bands of structural characterization of pro-
teins and provide clear information of any changes might occur due to various changes leading to decrease/increase in intensities of the original peaks as well as any shifts (blue/red due to interaction and or structural changes). HSA shows number of amide bands due to vibrations of various peptides within the protein.
[42] Specifically, the amide groups of the peptides represent characteristic vibrational modes (amide modes) which are sensitive to protein structures and any incurred changes might cause structural changes. IR spectral data for the HSA give rise to nine characteristic IR absorption bands, namely, amide A, B, and I-VII [43] [44] [45] . Amide I band ranges from 1700 to 1600 cm −1 and is mainly due to C=O stretching vibrations of the peptide linkages. Amide II in the range of 1600 -1480 cm −1 is due to the coupling of the N-H in-plane bending to C-N stretching vibration, while amide III band ranging from 1330 to 1220 cm −1 is due to the C-N stretching mode coupled to the in-plane N-H bending mode [45] . The FT-IR absorption spectra in the region of (1800 -1200) cm −1 are shown in Figure 7 for HSA and various HSA-DA complexes while HSA second derivatives are shown in Figure 7 for free HSA (bottom) and HSA-DA complexes (top) while the difference spectra corresponding to free HSA and HSA-DA complex with various DA concentrations are shown in Figure 8 . In addition, band assignments for the same spectra are presented in Table 1 . In amide III region, the only peak shift is on: 1294  1290 cm , which correspond to amide I and amide II, respectively represent the location of both the amide bonds orientation are sensitive to the HSA secondary structure because both groups of C=O and the N-H bonds are involved in the hydrogen bonding that takes place between the different elements of secondary structure [17] [46] . The overall change in peaks positions indicate HSA secondary structural changes due to interaction with DA. This shift in peak positions is mainly contributed to collisional electrostatic interaction between the HSA and the DA. Shifts to lower wavenumbers for the major peak in amide I i.e. 1656  1654 cm . Looking at the overall data in Table 1 , it is obvious that the peak change (appearance, disappearance or shift) was stabilized or reached a steady behavior when the ratio of DA to HSA was approaching 1, specifically when the DA concentration reached 0.6 mM which corresponds to 1:1 ratio with the HSA and beyond.
FT-IR spectra for the HSA-DA interaction are shown in Figure 8 . The FT-IR spectra (top two curves) and difference spectra {HSA-DA complex-HSA free} for HSA-DA different ratios complexes in amide I and amide II regions are clearly presented. There is no appearance of any new peaks or major shift in peak position. However, in amide I region, there is a negative peak at 1655 cm Percentage determination of the contribution of each secondary structural element in the HSA-DA complex secondary structure was carried out based on the assignment criterion for each of the HSA free and after the interaction with DA in amides I, II, and III. The quantitative analysis of the HSA was performed to determine any change in the secondary structure of HSA due to complexation with DA. The components bands of amide I, II, and III regions were assigned using have revealed that amid I bands are most sensitive in contributing to the secondary structure change however many studies reported informational contribution from amide II and III and can be used to study the secondary structure of protein. [50] [51] [52] .
In this work, the percentage of each secondary element of HSA secondary structure were calculated using normalization to integrate areas of the components bands in amide I, II, and III divided by the total area. The obtained values represent relative intensities for each of the secondary element with the specified region while the area under each secondary element corresponds to its percentage. Figure 10 shows the percentages determination for the secondary structure of HSA in amide I region. Similar figures were obtained for each of amide II and amide III regions. The obtained data in Table 2 is extracted from Figure 10 α-helix which is accompanied by decrease in β-sheets due to destabilization effects due to fast dynamic equilibrium which is consistent with the small binding constant value obtained from fluorescence in addition to weak hydrophobic contacts.
Discussion/Conclusions
In conclusion, the complexation of HSA-DA has been investigated using UV There are several ways to distinguish between dynamic and static quenching.
The first is to realize that upon complexation the newly formed complex usually has a different absorption spectrum from either of the complex components, therefore, changes on the absorption spectra are almost a diagnostic of a static quenching mechanism. The second hint usually is evident from the shape of the absorption spectra. Linear Stern-Volmer is almost always due to static quenching while non-linear is almost definitive criteria for either dynamic quenching due to purely collisional frequency or due to a mix of both static and dynamic quenching. Although dynamic and static processes are concurrently present in many systems, it is very important to realize the distinctive feature of the absorption spectra of such systems which result in an upward curvature which is not the case in HSA-DA system. Similar behavior in shape of the absorption spectra might be obtained in cases where there is more than one fluorophore accessible to the quencher i.e., DA. In such cases, DA quenched Trp214 fluorophores on the surface but was not able to penetrate the hydrophobic interior of be able to deliver DA directly. Possible ways to achieve this goal could be by either derivatization of DA or by using nanoparticles functionalization.
